期刊文献+

米氮平治疗抑郁症41例临床观察

下载PDF
导出
摘要 目的评价米氮平治疗抑郁症的疗效及安全性。方法将82例符合中国精神障碍分类与诊断标准(CCMD-3)有关抑郁症标准的患者,随机分成米氮平组和氟西汀组各41例,治疗6周。采用汉密尔顿抑郁量表(HAMD)、临床疗效总评量表(CGI)评定疗效,采用副反应量表(TESS)评定安全性。结果米氮平和氟西汀治疗抑郁症均有显著疗效,米氮平较氟西汀起效快,治疗第1周两组比较差异有显著性(P<0.05),两组TESS评分差异无显著性(P>0.05)。结论米氮平治疗抑郁症起效快、安全,值得临床推广应用。
出处 《广东药学院学报》 CAS 2007年第2期215-217,共3页 Academic Journal of Guangdong College of Pharmacy
  • 相关文献

参考文献13

  • 1司天梅,舒良,于欣,马崔,王高华,白培深,刘协和,纪丽萍,师建国,陈宪生,梅其一,栗克清,张鸿燕,马弘.抑郁障碍病人药物治疗的流行病学调查[J].中国神经精神疾病杂志,2004,30(2):81-84. 被引量:57
  • 2THOMPSON C,PEVELER R C,STEPHCNSON D,et a1.Compliance with antidepressant medication in the treatment of mjor depressive disorder in primary care:a randomized comparison of a tricyclic and atricyclic antidepressant[J].Am J Psychiatry,2000,157 (3):338-343.
  • 3COOKSON J.Side-effects of antidepressants[J].Br J Psychiatry,1993,163(suppl20):20-40.
  • 4COWEN P,POWER A C.Combination treatment of depression[J].Br J Psychiatry,1993,162:266-267.
  • 5ARYA D.Extrapyramidal symptoms with SSRIs[J].Br J Psychiatry,1994,165:728-733.
  • 6赵靖平.新型去甲肾上腺素能与特异性5-羟色胺能抗抑郁药米氮平[J].中华精神科杂志,2002,35(4):253-253. 被引量:66
  • 7KELLER M B,PINDER R M.The role of mirtazapine in the pharmcotherapy of depression[J].J Clin Psychiatry,2OOO,61:609-616.
  • 8王进良,曹磊明,刘晓伟,吴越,范洁,戴强.米氮平治疗抑郁症临床研究[J].临床精神医学杂志,2004,14(6):357-358. 被引量:21
  • 9THOMPSON C,PEVELER R C,PHCNSON D,et a1.Compliance with antidepressant medication in the treatment of major depressive disorder in primary care:a randomized comparison of fluoxetine and mirtazapine antidepressant[J].Am J Psychiatry,2000,157 (3):338-343.
  • 10DEMYTTEMYTTENAERE K,HADDAD P.Compliancewith antidepressant therapy and antidepressant discon-tinuation symptoms[J].Acta Psychiatr Scand Suppl,2000,403:50-56.

二级参考文献28

  • 1高静芳,陶明,张萍,唐文新.抗抑郁药物治疗的依从性观察[J].上海精神医学,2003,15(3):143-145. 被引量:23
  • 2王鹤秋,许本键,金枝,王素珍.文拉法辛缓释剂与氯米帕明治疗门诊抑郁症患者的比较[J].上海精神医学,2004,16(6):350-352. 被引量:6
  • 3沈渔邨.精神病学(第3版)[M].北京:人民卫生出版社,1995.917.
  • 4Lin?EH, Von Korff?M, Katon?W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy.Med Care 1995,Jan 33:67.
  • 5Tai-Seale M, Croghan TW, Obenchain R.. Determinants of antidepressant treatment compliance: implications for policy. Med Care Res, Rev 2000, Dec,57(4):491.
  • 6Keller MB, Hirschfeld RM, Demyttenaere K, et al. Optimizing outcomes in depression., focus on antidepressant compliance [In Process Citation] Int Clin Psychopharmacol, 2002, Nov, 17(6):265.
  • 7Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr Scand, Suppl 2000,403 : 50.
  • 8赵振文 张国环 张婷婷.我院1998年—2000年抗抑郁药物用药趋势分析[J].中国临床医药研究杂志,2002,64(1):50-50.
  • 9黄恩 施剑英.抗抑郁药的门诊应用情况分析[J].国际中华神经精神医学杂志,2001,2(4):216-216.
  • 10Preskorn SH.Antidepressant drug selection: criteria and options.J Clin Psychiatry, 1994,55(suppl A):6.

共引文献135

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部